FCRL2 and B-cell chronic lymphocytic leukemia: Median TFT was 36.4 years for FCRL2-positive patients with M-CLL as compared to only 8.75 years for FCRL2-negative patients with M-CLL (HR 3.31, 95%CI 0.465–23.6, P < 0.05, Fig. 1e).